AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20942287 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at non‐acupoints compound general anesthesia (group C)
Number of subjects: 90
Study 20942287 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group A)
Number of subjects: 90
Study 18380632 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin arm of SPORTIF III
Number of subjects: 381
Study 16253496 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation program
Number of subjects: 26
Study 16253496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 14636097 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% of 1 repetition maximum (n = 9)
Number of subjects: 24
Study 14636097 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% of 1 repetition maximum (n = 9)
Number of subjects: 24
Study 14636097 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 24
Study 10917401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 to 200 mg/day) combined with neuroleptics
Number of subjects: 30
Study 10917401 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics only
Number of subjects: 30
Study 8702053 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) infusion (20 ng/kg bw/min)
Number of subjects: 9
Study 8702053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8702053 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) infusion
Number of subjects: 9
Study 1687130 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (6, 18 and 54 micrograms)
Number of subjects: 9
Study 1687130 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100, 300 and 900 micrograms)
Number of subjects: 9
Study 1687130 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg Salbutamol (after last dose)
Number of subjects: 9
Study 1687130 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Formoterol and Salbutamol
Number of subjects: 9
Study 6395349 — intervention group
Group type: EXPERIMENTAL
Intervention: Furapyrimidone
Number of subjects: 218
Study 6395349 — intervention group
Group type: COMPARATOR
Intervention: Hetrazan
Number of subjects: 218
Study 30883497 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of trunk-specific exercise
Number of subjects: 24
Study 30883497 — intervention group
Group type: COMPARATOR
Intervention: Education (control group)
Number of subjects: 24
Study 29851804 — intervention group
Group type: EXPERIMENTAL
Intervention: Video narratives intervention
Number of subjects: 200
Study 29851804 — intervention group
Group type: COMPARATOR
Intervention: Standard patient education care (Control)
Number of subjects: 200
Study 26782254 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with primary tumor resection (PTR)
Number of subjects: 480
Study 26782254 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 480
Study 25007865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg once daily
Number of subjects: 0
Study 25007865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg once daily
Number of subjects: 0
Study 25007865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg and 200 μg once daily
Number of subjects: 0
Study 22377389 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 0
Study 22377389 — intervention group
Group type: COMPARATOR
Intervention: NRT
Number of subjects: 0
Study 22377389 — intervention group
Group type: COMPARATOR
Intervention: varenicline-placebo
Number of subjects: 0
Study 21055090 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized dust mite allergen specific immunotherapy (SIT)
Number of subjects: 85
Study 21055090 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (control group)
Number of subjects: 85
Study 17334147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water irrigation
Number of subjects: 0
Study 17334147 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 0
Study 15802694 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise
Number of subjects: 105
Study 15802694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 105
Study 12766091 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 47
Study 12766091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10559514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of LNMMA (8 and 16 micromol/min) followed by intracoronary administration of 250 mcg nitroglycerin
Number of subjects: 30
Study 10559514 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary infusion of LNMMA
Number of subjects: 30
Study 8565164 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-18790 (5 micrograms.kg‐1.min‐1, low dose)
Number of subjects: 17
Study 8565164 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-18790 (10 micrograms.kg‐1.min‐1, high dose)
Number of subjects: 17
Study 1683557 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 448
Study 1683557 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 448
Study 1683557 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 448
Study 6129869 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 20 mg 3 times a day
Number of subjects: 30
Study 6129869 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate 4 mg 3 times a day
Number of subjects: 30
Study 6129869 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (up to 200 mg 3 times a day)
Number of subjects: 30
Study 6129869 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 30
Study 31864496 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping twice before testicular tissue collection
Number of subjects: 20
Study 31864496 — intervention group
Group type: COMPARATOR
Intervention: Stripping once
Number of subjects: 20
Study 31864496 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular tissue collection combined with stripping
Number of subjects: 20
Study 30968801 — intervention group
Group type: EXPERIMENTAL
Intervention: Host plant cultivar
Number of subjects: 0
Study 30968801 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasitism
Number of subjects: 0
Study 30968801 — intervention group
Group type: EXPERIMENTAL
Intervention: Host-plant-adapted aphid species
Number of subjects: 0
Study 30177462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Everolimus (BV + EV)
Number of subjects: 150
Study 30177462 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone (BV)
Number of subjects: 150
Study 27090299 — intervention group
Group type: EXPERIMENTAL
Intervention: Future Care Planning (FCP) for 12 weeks upon discharge
Number of subjects: 50
Study 27090299 — intervention group
Group type: EXPERIMENTAL
Intervention: Future Care Planning (FCP)
Number of subjects: 50
Study 27090299 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 12 weeks upon discharge
Number of subjects: 50
Study 25165723 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 20
Study 25165723 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 20
Study 23297562 — intervention group
Group type: EXPERIMENTAL
Intervention: sidong wubu method for 6 months
Number of subjects: 654
Study 23297562 — intervention group
Group type: COMPARATOR
Intervention: open reduction and internal fixation (control group)
Number of subjects: 654
Study 23297562 — intervention group
Group type: EXPERIMENTAL
Intervention: sidong wubu method
Number of subjects: 654
Study 18815772 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nicotine via nasal spray
Number of subjects: 0
Study 18815772 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo via nasal spray
Number of subjects: 0
Study 17804334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 176
Study 17804334 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 176
Study 17804334 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement (ZPC)
Number of subjects: 176
Study 17804334 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper bands cemented with ZPC
Number of subjects: 176
Study 17804334 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 176
Study 17804334 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 176
Study 16035374 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic multivitamin and mineral supplement (verum)
Number of subjects: 477
Study 16035374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 11986138 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based skills training supplemented with manual-based generalization sessions in the community
Number of subjects: 63
Study 11986138 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based skills training alone
Number of subjects: 63
Study 9661595 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (mid and high doses)
Number of subjects: 55
Study 9661595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen (late pubertal dose)
Number of subjects: 55
Study 9661595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7715103 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting MIBG SPECT
Number of subjects: 49
Study 7715103 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting BMIPP SPECT
Number of subjects: 49
Study 7715103 — intervention group
Group type: COMPARATOR
Intervention: Exercise Tl SPECT
Number of subjects: 49
Study 7715103 — intervention group
Group type: COMPARATOR
Intervention: Resting Tl SPECT
Number of subjects: 49
Study 2655812 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg, 2 to 5 tablets twice a week for 1 year)
Number of subjects: 297
Study 2655812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 2655812 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 297
Study 332218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 32
Study 332218 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 32
Study 332218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30895578 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diabetes testing (HBA1c, 50 g glucose challenge test, or 100 g oral glucose tolerance test) before 24 weeks
Number of subjects: 2698
Study 30895578 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diabetes testing
Number of subjects: 2698
Study 31494015 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Minds-Strong Bodies (PMSB) intervention
Number of subjects: 307
Study 31494015 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 307
Study 28344197 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-CA administered after a meal
Number of subjects: 42
Study 28344197 — intervention group
Group type: COMPARATOR
Intervention: OM3-CA administered in fasting conditions
Number of subjects: 42
Study 28344197 — intervention group
Group type: COMPARATOR
Intervention: OM3-CA administered before a meal
Number of subjects: 42
Study 28344197 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 42
Study 28344197 — intervention group
Group type: COMPARATOR
Intervention: Before meal condition
Number of subjects: 42
Study 28344197 — intervention group
Group type: EXPERIMENTAL
Intervention: After meal condition
Number of subjects: 42
Study 26447705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) with local anesthetic and saline, three 120 second cycles per targeted nerve
Number of subjects: 81
Study 26447705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 81
Study 26447705 — intervention group
Group type: COMPARATOR
Intervention: Steroid injections with local anesthetic mixed with deposteroid and 3 rounds of sham PRF
Number of subjects: 81
Study 23643652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) in advanced to 50% of maximum protrusion (A50) position for 1 week
Number of subjects: 16
Study 23643652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) for snorers (n=8)
Number of subjects: 16
Study 23643652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (MAA) for headache assessment
Number of subjects: 16
Study 21277403 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 261
Study 21277403 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated controls
Number of subjects: 261
Study 19808130 — intervention group
Group type: EXPERIMENTAL
Intervention: ARF15 BID (15 microg/2 mL twice daily)
Number of subjects: 33
Study 19808130 — intervention group
Group type: EXPERIMENTAL
Intervention: ARF30 QD (30 microg/4 mL once daily)
Number of subjects: 33
Study 16394955 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (750 mg daily for 10 days)
Number of subjects: 14
Study 16394955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15700504 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent smoking intervention (during alcohol treatment)
Number of subjects: 499
Study 15700504 — intervention group
Group type: COMPARATOR
Intervention: Delayed smoking intervention (6 months later)
Number of subjects: 499
Study 15700504 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent smoking intervention
Number of subjects: 499
Study 15700504 — intervention group
Group type: COMPARATOR
Intervention: Delayed smoking intervention
Number of subjects: 499
Study 11711507 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol reduction
Number of subjects: 2234
Study 11711507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol reduction)
Number of subjects: 2234
Study 9161369 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric (CON) isokinetic measurements at 60 degrees/sec and 180 degrees/sec
Number of subjects: 16
Study 9161369 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) isokinetic measurements at 60 degrees/sec and 180 degrees/sec
Number of subjects: 16
Study 9161369 — intervention group
Group type: COMPARATOR
Intervention: Menstrual cycle phases (MP, FP, LP)
Number of subjects: 16
Study 7956548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 5980
Study 7956548 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous onset of labor (Control)
Number of subjects: 5980
Study 2953527 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene D4 (LTD4) inhalation
Number of subjects: 33
Study 2953527 — intervention group
Group type: COMPARATOR
Intervention: Histamine inhalation
Number of subjects: 33
Study 2953527 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide pretreatment
Number of subjects: 33
Study 2953527 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine and mepyramine or indomethacin pretreatment
Number of subjects: 33
Study 31225688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional vitamin D3
Number of subjects: 60
Study 31225688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen
Number of subjects: 60
Study 31225688 — intervention group
Group type: COMPARATOR
Intervention: Intralesional saline (control)
Number of subjects: 60
Study 29354988 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation) for 30 min at bilateral Zusanli (ST 36) and Neiguan (PC 6) with frequency of 5 Hz and intensity 1 mA lower than tolerance threshold.
Number of subjects: 75
Study 29354988 — intervention group
Group type: COMPARATOR
Intervention: Sham group (stimulated at the same acupoints with current intensity 1 mA lower than sensory threshold).
Number of subjects: 75
Study 29354988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 75
Study 26271173 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent polysaccharide conjugate vaccine (PCV13)
Number of subjects: 84496
Study 26271173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84496
Study 23595153 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose twice-daily nevirapine
Number of subjects: 162
Study 23595153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine dose-escalation
Number of subjects: 162
Study 21166598 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg)
Number of subjects: 225
Study 21166598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 225
Study 18359215 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable Oxygen Concentrator (POC)
Number of subjects: 13
Study 18359215 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Oxygen (LO)
Number of subjects: 13
Study 18359215 — intervention group
Group type: COMPARATOR
Intervention: Compressed Air (CA)
Number of subjects: 13
Study 18359215 — intervention group
Group type: EXPERIMENTAL
Intervention: POC
Number of subjects: 13
Study 18359215 — intervention group
Group type: EXPERIMENTAL
Intervention: LO
Number of subjects: 13
Study 18359215 — intervention group
Group type: COMPARATOR
Intervention: CA
Number of subjects: 13
Study 16926261 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist triptorelin 0.1 mg administered on day 6 after ICSI
Number of subjects: 600
Study 16926261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 15523311 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 198
Study 15523311 — intervention group
Group type: COMPARATOR
Intervention: Medical stabilization
Number of subjects: 198
Study 10742707 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg once daily
Number of subjects: 31
Study 10742707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10742707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (celiprolol and placebo)
Number of subjects: 31
Study 9059768 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM)
Number of subjects: 550
Study 9059768 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus (NIDDM)
Number of subjects: 550
Study 9059768 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 550
Study 9059768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropical diabetes
Number of subjects: 550
Study 8405139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode I: 20 mg hydrocortisone (HC) at 0700 h and 10 mg HC at 1900 h
Number of subjects: 14
Study 8405139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode II: 30 mg HC at 0700 h and placebo at 1900 h
Number of subjects: 14
Study 8405139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode III: Placebo at 0700 h and 30 mg HC at 1900 h
Number of subjects: 14
Study 8405139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode I
Number of subjects: 14
Study 3950220 — intervention group
Group type: EXPERIMENTAL
Intervention: High social reinforcement verbal self-instructional (VSI) training group
Number of subjects: 24
Study 3950220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social reinforcement verbal self-instructional (VSI) training group
Number of subjects: 24
Study 3950220 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 24
Study 30114712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided thoracic paravertebral block
Number of subjects: 145
Study 30114712 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia
Number of subjects: 145
Study 29364343 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated glass ionomer cement (GIC; Riva Self‐Cure, SDI)
Number of subjects: 40
Study 29364343 — intervention group
Group type: COMPARATOR
Intervention: Hand-mixed glass ionomer cement (GIC)
Number of subjects: 40
Study 26985905 — intervention group
Group type: COMPARATOR
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 26
Study 24812492 — intervention group
Group type: EXPERIMENTAL
Intervention: Old 'sticky' tablet
Number of subjects: 0
Study 24812492 — intervention group
Group type: COMPARATOR
Intervention: New tablet formulations (larger API crystal size, 30% more excipients)
Number of subjects: 0
Study 24812492 — intervention group
Group type: COMPARATOR
Intervention: 25 mg and 50 mg liquid‐filled hard gelatin capsule
Number of subjects: 0
Study 24812492 — intervention group
Group type: COMPARATOR
Intervention: 100 mg reference tablet
Number of subjects: 0
Study 22192272 — intervention group
Group type: EXPERIMENTAL
Intervention: History of TB
Number of subjects: 23901
Study 22192272 — intervention group
Group type: EXPERIMENTAL
Intervention: Past TB
Number of subjects: 23901
Study 22192272 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination during the first year of life
Number of subjects: 23901
Study 20459368 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow excision (2 cm margins)
Number of subjects: 144
Study 20459368 — intervention group
Group type: COMPARATOR
Intervention: Wide excision (4 cm margins)
Number of subjects: 144
Study 17664470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin reintroduction
Number of subjects: 0
Study 17664470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin reintroduction > 40%
Number of subjects: 0
Study 16051519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme (patient education, consultation with cardiologist, monitoring in Heart Failure Unit)
Number of subjects: 153
Study 16051519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme
Number of subjects: 153
Study 16051519 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study 11851638 — intervention group
Group type: EXPERIMENTAL
Intervention: S 18326 (0.5 mg h‐1)
Number of subjects: 36